Frits H.A.F. de Man

Showing 1-12 of 12 articles

Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT

Zocca P, van der Heijden LC, Kok M, Löwik M, Hartmann M, Stoel M, Louwerenburg H, de Man F, Linssen GCM, Knottnerus I, Doggen CJM, van Houwelingen K, von Birgelen C

November 20, 2017 | 10.4244/EIJ-D-17-00634

Coronary interventions

Value of the SYNTAX score for periprocedural myocardial infarction according to WHO and the third universal definition of myocardial infarction: insights from the TWENTE trial

Tandjung K, Lam MK, Sen H, de Man F, Louwerenburg H, Stoel M, van Houwelingen K, Linssen GCM, van der Palen J, Doggen CJM, von Birgelen C

July 20, 2016 | 10.4244/EIJY15M08_01

Coronary interventions

Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAYA study

Kok M, von Birgelen C, Lam MK, Löwik M, van Houwelingen K, Stoel M, Louwerenburg H, de Man F, Hartmann M, Doggen CJM, van Til J, IJzerman M

April 20, 2016 | 10.4244/EIJY15M10_06

Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial

Lam MK, Tandjung K, Sen H, Basalus M, van Houwelingen K, Stoel M, Louwerenburg H, Linssen GCM, Said S, Nienhuis M, de Man F, van der Palen J, von Birgelen C

June 19, 2015 | 10.4244/EIJV11I2A32

Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial

Löwik M, Lam MK, Sen H, Tandjung K, van Houwelingen K, de Man F, Stoel M, Louwerenburg H, Linssen GCM, Doggen CJM, von Birgelen C

March 20, 2015 | 10.4244/EIJY14M08_11

Assessment of the relation between initial culprit vessel patency in acute ST-elevation myocardial infarction and endothelial function

Kandhai-Ragunath J, Jorstad H, de Wagenaar B, de Man F, Stoel M, van Es J, Doelman CJA, Doggen CJM, Peters R, von Birgelen C

November 20, 2014 | 10.4244/EIJV10I7A137

Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial

Sen H, Lam MK, Tandjung K, Basalus M, de Man F, Louwerenburg H, Stoel M, van Houwelingen K, Löwik M, Linssen GCM, Said S, Nienhuis M, Verhorst P, van der Palen J, von Birgelen C

October 20, 2014 | 10.4244/EIJV10I6A117

Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and XIENCE V drug-eluting stents

Sen H, Tandjung K, Basalus M, L M, van Houwelingen K, Stoel M, Louwerenburg H, de Man F, Linssen GCM, Nijhuis R, Nienhuis M, Verhorst P, van der Palen J, von Birgelen C

October 26, 2012 | 10.4244/EIJV8I6A104

Usefulness and safety of the GuideLiner catheter to enhance intubation and support of guide catheters: insights from the Twente GuideLiner registry

de Man F, Tandjung K, Hartmann M, van Houwelingen K, Stoel M, Louwerenburg H, Basalus M, Sen H, Löwik M, von Birgelen C

July 27, 2012 | 10.4244/EIJV8I3A52

Scanning electron microscopic assessment of the biodegradable coating on expanded biolimus-eluting stents

Basalus M, van Houwelingen K, Ankone M, de Man F, von Birgelen C

September 30, 2009

Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy

Basalus M, Ankone M, van Houwelingen K, de Man F, von Birgelen C

May 19, 2009

Registry on a new T technique for bifurcation coronary lesions: the Utrech-"T"- experience

Pavlakis G, de Man F, Hamer B, Doevendans P, Stella P

August 20, 2007

Latest news

NEW ISSUE

Infective Endocarditis & TAVI; Cerebral Protection Devices; IVUS Assessment in ViV-TAVI, Mini Focus on Antithrombotic Therapy …

February 19, 2021

News

Don’t Miss #EIJOnAir 2nd Edition!

Elective cardiac invasive procedures during the COVID-19 outbreak

March 4, 2021

Ahead of Print

MitraClip for a range of LV dysfunction and secondary MR

Stamatios Lerakis et al.

March 2, 2021

Editorial

Thrombolysis in ST-elevation myocardial infarction is not dead

Petr Kala et al.

March 2, 2021

SCOPE 2, COACT 1 year, FORZA, COMPARE CRUSH

(Thanks to the support of Biotronik)

February 28, 2021

JAA

This Week's JAA's: Impact of crossing strategy on CTO recanalisation outcomes and more...

March 2, 2021

Guidance Papers

Guidelines, consensus & position papers